

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4737185

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
VERTEX PHARMACEUTICALS (SAN DIEGO) LLC	09/29/2017
RECEIVING PARTY DATA	
Name:	VERTEX PHARMACEUTICALS INCORPORATED
Street Address:	50 NORTHERN AVENUE
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02210
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15721390
PCT Number:	US2017054611
CORRESPONDENCE DATA	
Fax Number:	(617)646-1666
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6176461683
Email:	karen.young@finnegan.com
Correspondent Name:	CHRISTINA RODRIGO
Address Line 1:	901 NEW YORK AVENUE NW
Address Line 2:	FINNEGAN
Address Line 4:	WASHINGTON, D.C. 20001
ATTORNEY DOCKET NUMBER:	10275.0116-00000 & 00304
NAME OF SUBMITTER:	CHRISTINA M. RODRIGO, PH.D.
SIGNATURE:	/Christina Rodrigo/
DATE SIGNED:	12/15/2017
Total Attachments: 2	
source=16-127 WO Executed Assignment Vertex San Diego to Vertex MA#page1.tif	
source=16-127 WO Executed Assignment Vertex San Diego to Vertex MA#page2.tif	

ASSIGNMENT

WHEREAS We, Vertex Pharmaceuticals (San Diego) LLC, a company organized and existing under the laws of Delaware whose post office address is 11010 Torreyana Road, San Diego, California 92121, USA (hereinafter referred to as Assignor(s)), of an invention entitled:

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

as disclosed and claimed in the applications identified below this paragraph:

Application Number	Country of Filing	Filing Date
PCT/US2017/059611	PCT	September 29, 2017
151721, 390	US	September 29, 2017
P20170102750	AR	October 2, 2017
106133964	TW	September 30, 2017
37428	UY	October 2, 2017
2017-000377	VE	October 3, 2017

which claim priority to U.S. Provisional Application No. 62/402,838 filed on September 30, 2016, U.S. Provisional Application No. 62/410,353 filed on October 19, 2016, U.S. Provisional Application No. 62/415,409 filed on October 31, 2016, and U.S. Provisional Application No. 62/419,935 filed on November 9, 2016;

WHEREAS, Vertex Pharmaceuticals Incorporated, a corporation of Massachusetts whose post office address is 50 Northern Avenue, Boston, MA, USA (hereinafter referred to as Assignee), is desirous of securing the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;

NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, We, as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and We hereby authorize and request the any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that We have the full right to convey the interest assigned by this Assignment, and We have not executed and will not execute any agreement in conflict with this Assignment;

AND, WE further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to me/us respecting this invention, and testify in any legal proceeding, sign all
Page 1 of 2

lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

AND, WE authorize and request a patent practitioner of record in this application, to insert the filing date, country of filing, and application number of the above-referenced applications when known.

IN TESTIMONY WHEREOF, We have hereunto set our hands.


On behalf of Vertex Pharmaceuticals (San Diego) LLC



Name: Kerry A. Flynn
Title: Vice President, IP and Chief IP Counsel
Vertex Pharmaceuticals (San Diego) LLC
Date: September 29, 2017

ACKNOWLEDGEMENT OF ASSIGNEE

On behalf of Vertex Pharmaceuticals Incorporated



Name: Kerry A. Flynn
Title: Vice President, IP and Chief IP Counsel
Vertex Pharmaceuticals Incorporated
Date: September 29, 2017